Advances in Hormone Receptor Positive Metastatic Breast Cancer

Recommendations for managing HR-positive, HER2-negative metastatic breast cancer with CDK4/6 inhibitors and endocrine therapy.

EP. 1: Treatment Advances in HR+ Advanced Breast Cancer

October 27th 2021

Aditya Bardia, MD, MPH, discusses the current standard of care for HR+ advanced breast cancer and reacts to treatment advances with the availability of CDK4/6 inhibitors.

EP. 2: First-Line Approaches for HR+ Metastatic Breast Cancer

November 10th 2021

Options available as first-line therapy for HR+ metastatic breast cancer and variables that impact which CDK4/6 inhibitor and endocrine partner is selected for a patient.

EP. 3: Updates to MONALEESA-2 Data in HR+ MBC

November 10th 2021

Important takeaways from MONALEESA-2 trial updates on overall survival data corresponding with the use of ribociclib plus letrozole, as presented at ESMO 2021.

EP. 4: HR+ MBC: Ribociclib and Patient Quality of Life

November 17th 2021

Considerations for treating HR+ metastatic breast cancer with ribociclib plus endocrine therapy based on quality-of-life metrics demonstrated by a recent ESMO 2021 presentation.

EP. 5: HR+ MBC: Abemaciclib Plus Endocrine Therapy

November 22nd 2021

Clinical implications of a pooled analysis of endocrine therapy-naïve participants in MONARCH 2 investigating the use of abemaciclib plus fulvestrant to treat hormone receptor-positive metastatic breast cancer.

EP. 6: HR+ MBC: Palbociclib Plus Endocrine Therapy on Time to Chemotherapy

November 22nd 2021

The rationale for conducting a post-hoc analysis of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor-positive metastatic breast cancer as presented at ESMO 2021.

EP. 7: HR+ MBC: Genomic Testing and Treatment Guidance

November 29th 2021

A discussion on the current utilization of molecular testing in patients with HR-positive metastatic breast cancer, and recommendations for conducting liquid and tissue biopsies to help inform treatment decisions.

EP. 8: PI3K Inhibitors for HR+ MBC

November 29th 2021

The relevance of PIK3CA mutations in terms of the pathophysiology of HR-positive metastatic breast cancer, and lessons learned in practice and via clinical studies in terms of sequencing therapy with PI3K inhibitors.

EP. 9: Novel Therapies Under Investigation for HR+ MBC

December 6th 2021

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

EP. 10: Advances Treating HR+ Metastatic Breast Cancer

December 6th 2021

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.